PMID- 27760066
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171128
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 68
IP  - 4
DP  - 2016 Oct
TI  - The Impact of Allopurinol on Patients With Acute ST Elevation Myocardial 
      Infarction Undergoing Thrombolytic Therapy.
PG  - 265-268
AB  - Allopurinol may have protective effects over ischemic reperfusion injury and 
      reduce infarct size. In this randomized study, we aimed to evaluate the impact of 
      allopurinol in patients with acute ST elevation myocardial infarction (STEMI) 
      undergoing thrombolytic therapy. Overall, 140 patients with STEMI were randomly 
      assigned to receive 400 mg of allopurinol or placebo before treating with 
      streptokinase. Then, study group received 100 mg of allopurinol daily for 28 days 
      and placebo group received placebo for the same period. ST resolution rate in 90 
      minutes, in-hospital mortality, and major adverse cardiac events (MACE) were 
      compared. Compared to placebo group, patients receiving allopurinol had 
      significantly higher rate of ST resolution rate >/=50% (68.8% vs. 50%, P = 0.04) 
      and lower levels of peak Creatine kinase (CK) (P = 0.003), Creatine Kinase-MB 
      (CK-MB) (P = 0.005), and Cardiac Troponin I (CTnI) (P < 0.001). Also, patients in 
      allopurinol group had significantly lower rate of in-hospital MACE (P = 0.03), 
      but there was no significant difference between groups regarding in-hospital 
      mortality and cardiac events. In patients admitted with STEMI who are candidates 
      of thrombolytic therapy, allopurinol is associated with better 90-minute ST 
      resolution, lower enzymatically determined infarct size, and in-hospital MACE. 
      More powerful studies are needed to determine the effect on mortality.
FAU - Separham, Ahmad
AU  - Separham A
AD  - *Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran; anddaggerDepartment of Pharmacology & Applied Medicine, Medicinal Plants 
      Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran;double daggerDrug Applied 
      Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Ghaffari, Samad
AU  - Ghaffari S
FAU - Najafi, Hossein
AU  - Najafi H
FAU - Ghaffari, Reza
AU  - Ghaffari R
FAU - Ziaee, Mojtaba
AU  - Ziaee M
FAU - Babaei, Hossein
AU  - Babaei H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Free Radical Scavengers)
RN  - 63CZ7GJN5I (Allopurinol)
SB  - IM
MH  - Aged
MH  - Allopurinol/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Free Radical Scavengers/therapeutic use
MH  - Hospital Mortality/trends
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - ST Elevation Myocardial Infarction/diagnosis/*drug therapy/*mortality
MH  - Thrombolytic Therapy/*adverse effects/*mortality/trends
EDAT- 2016/10/21 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/10/21 06:00
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/10/21 06:00 [entrez]
AID - 00005344-201610000-00002 [pii]
AID - 10.1097/FJC.0000000000000409 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2016 Oct;68(4):265-268. doi: 
      10.1097/FJC.0000000000000409.